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Abstract
Background: Past studies have found a relationship between detectable HIV viral load and non-communicable
diseases (NCDs) in HIV-infected individuals on antiretroviral therapy in high-income settings, however there is little
research in South Africa. Our objective was to investigate the association between detectable HIV viral load and
prevalent NCDs in a primary health centre in peri-urban South Africa.
Methods: HIV-infected adults (aged ≥25) who had been on antiretroviral therapy for ≥ six months and attended
the HIV clinic within a primary health centre in Khayelitsha, Cape Town, were recruited. We recorded participants’
demographics, HIV characteristics, the presence of NCDs via self-report, from clinic folders and from measurement
of their blood pressure on the day of interview. We used logistic regression to estimate the association between a
detectable HIV viral load and NCD comorbidity.
Results: We recruited 330 adults. We found no association between a detectable HIV viral load and NCD
comorbidity. Within our multivariable model, female gender (OR3·26; p = 0·02) age > 35 (OR 0·40; p = 0·02) low CD4
count (compared to CD4 < 300 (reference category): CD4:300–449 OR 0·28; CD4:450–599 OR 0·12, CD4:≥600 OR
0·12; p = < 0·001), and ever smoking (OR 3·95; p = < 0·001) were associated with a detectable HIV viral load. We
found a lower prevalence of non-communicable disease in clinic folders than was self-reported. Furthermore the
prevalence of hypertension measured on the day of interview was greater than that reported on self-report or in
the clinic folders.
Conclusions: The lack of association between detectable viral load and NCDs in this setting is consistent with
previous investigation in South Africa but differs from studies in high-income countries. Lower NCD prevalence in
clinic records than self-report and a higher level of hypertension on the day than self-reported or recorded in clinic
folders suggest under-diagnosis of NCDs in this population. This potential under-detection of NCDs may differ from
a high-income setting and have contributed to our finding of a null association. Our findings also highlight the
importance of the integration of HIV and primary care systems to facilitate routine monitoring for non-
communicable diseases in HIV-infected patients.
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Background
The rollout of antiretroviral therapy (ART) across
Sub-Saharan Africa (SSA) has dramatically increased the
life expectancy of those initiated on ART. As this popu-
lation ages, they become increasingly susceptible to
age-related comorbidity. An “accelerated ageing” syn-
drome has been described where deleterious features as-
sociated with ageing emerge decades earlier in
HIV-infected individuals [1, 2]. Contributing factors are
thought to be HIV itself and the effect of long term
ART [2, 3].
To ensure optimal care for aging HIV-infected individ-
uals, there is a need to recognize the association be-
tween comorbidity and HIV. Studies on ART patients
have demonstrated the association between a detectable
HIV viral load and a greater risk of developing comor-
bidities [4–6]. However, these studies were based in
high-income settings where the HIV epidemic is not
generalised. The rising prevalence of non-communicable
diseases (NCDs) in SSA, combined with high levels of
chronic infectious diseases such as HIV is resulting in a
different pattern of multimorbidity than is seen in
high-income countries [3]. Low-income groups in South
Africa (SA) have seen a dramatic increase in prevalence
of NCDs and have the highest burden of HIV, a chronic
infectious disease resulting in concurrent epidemics [7].
The new ART initiation guidelines in SA will increase
the numbers of patients on ART [8]. However, little is
known about the impact of comorbid chronic diseases
on long-term HIV management and care necessitating
further research to better understand the association be-
tween NCD comorbidity and HIV control. In SA, NCD
management is largely in primary care clinics, with treat-
ment freely available. In the Western Cape province, pri-
mary care clinics are organised into disease-specific
clubs, with a focus on four diseases (based on prevalence
and importance as determined by contribution to dis-
ability adjusted life years, and the need for specialist ex-
pertise input in the primary care setting): diabetes,
hypertension, asthma/chronic obstructive pulmonary
disease, and epilepsy. The province-wide annual chronic
disease audit conducted by the provincial government
department of health, focuses on these diseases with the
aim of improving management and disease outcomes.
Yet, despite the increasing co-morbidity of NCDs with
HIV in SA and an increasing body of research in
high-income countries on the association between a de-
tectable HIV load and NCDs, there is little known about
the association between HIV and these diseases in low
and middle-income settings [3–6]. The objective of this
study was therefore to examine the association between
prevalent NCDs of importance in this setting (hyperten-
sion, diabetes, epilepsy or chronic respiratory disease
(CRD)) and a current detectable HIV viral load.
Methods
The study was conducted in Ubuntu ART clinic, in
Khayelitsha, the largest township on the outskirts of
Cape Town, SA with approximately 500,000 predomin-
antly black Africans and over 8000 HIV-infected individ-
uals registered on ART [9, 10]. While Ubuntu clinic is
located in a healthcare delivery complex that provides
outpatient primary care services for NCDs, these facil-
ities have separate buildings, staff and separate pharma-
cies; and represent non-integrated health systems. As a
result, each HIV-infected patient at Ubuntu clinic has a
clinic folder for ART only and (if diagnosis known) a
separate folder for other primary health care services, in-
cluding NCDs. There was no routine screening for
NCDs in the ART clinic. Any recording of NCDs or at-
tempt at screening was entirely based on the clinician’s
decision at the time of consultation. As a result, there
were no NCD data in many of the HIV clinic folders re-
gardless of on-going care for NCDs in the primary
healthcare clinic. The NCDs routinely managed in the
primary care outpatient clinic and in routine NCD ad-
herence clubs are diabetes, hypertension, CRD and epi-
lepsy, in line with Western Cape Department of Health
policy which annually audits these specific conditions
[10].
Recruitment was from 13th January 2015 until 14th
February 2015. During this period, as patients arrived at
the clinic, staff transferred their HIV clinic folder to the
clinic reception, where SG would screen the folders of
the first ten patients for eligibility, and all those eligible
were invited to participate. Once those eligible had par-
ticipated, the next available ten folders were screened,
this system was continued until the sample size was
reached. Eligibility criteria were aged 25 years and older,
on ART for at least 6 months and not knowingly preg-
nant at the time of interview. All participants gave writ-
ten informed consent and interviews were conducted in
a private clinic room on the same day. During the inter-
view, data on the patient’s age, sex, current and past
smoking habit, self-reported previously diagnosed co-
morbidities: hypertension, diabetes, chronic respiratory
disease (CRD), and epilepsy were collected through ad-
ministration of a questionnaire. These NCDs were se-
lected as a priority due to their high prevalence in this
population. In addition, these conditions represent
health system priorities for the Western Cape province,
as evidenced by the fact that NCD weekly outpatient
clinics and adherence clubs exist for these conditions,
and that the Department of Health annual audit for
NCDs focuses on these conditions as a part of primary
care service provision [4, 6, 10, 11]. The diagnosis of
these NCDs is in line with guidelines set out by the
South African government for primary care [12]. Specif-
ically hypertension was diagnosed based on two elevated
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(> 140/90) blood pressure readings, diabetes diagnosed
on the basis of a random blood glucose measurement >
11 and fasting blood glucose > 7, CRD was a clinical
diagnosis based on symptoms and risk factors as set out
in the primary care guidelines [12], and epilepsy diag-
nosed by a physician with specialist expertise based on
the presence of two seizures with no other clear cause.
Including diabetes and hypertension enabled compari-
sons to be made with multimorbidity studies conducted
in this setting [2]. Measurements (height, weight, and
blood pressure using an electronic blood pressure ma-
chine) were taken once at the end of the interview by
SG. The same technique and electronic blood pressure
machine was used throughout the data collection period.
After interview, the following data were extracted from
the patient’s clinic folder and any missing data was ex-
tracted from the national health electronic laboratory
service database: most recent viral load and CD4 count
and date of ART initiation. This electronic database is
an established national centralised service for the public
healthcare system, with standard operating procedures
for all tests, within which each patient, irrespective of
what clinic they are seen, is identified via a unique iden-
tifier [13]. The primary outcome was a detectable viral
load at the most recent viral load measurement, defined
as > 40 copies/ml. We calculated that a sample size of
330 participants was sufficient to detect a two-fold
higher proportion of patients with a detectable viral load
among those with comorbidity compared to those
with no comorbidity, with a power of 0·8 and an
alpha level of 0·05, while assuming that half of the
HIV population in the clinic would have at least one
comorbidity listed above.
Four indicators of comorbidity (hypertension, diabetes,
CRD and/or epilepsy) were created: i) comorbidity re-
ported in clinic folder; ii) self-reported comorbidity dur-
ing interview; iii) comorbidity reported in clinic folder
OR on self-report during interview, and iv) a composite
indicator consisting of comorbidity indicator (iii) (co-
morbidity reported in clinic folder OR self-report during
interview) plus measured hypertension (diastolic ≥90
mmHg or a systolic ≥140 mmHg in line with SAGE,
NIDS and SANHANES-1 studies [14, 15]) on the day of
interview. These definitions of comorbidity are referred
to throughout the rest of the manuscript as comorbidity
indicators i, ii, iii, and iv. Comorbidity indicator iii was
also used to generate a variable representing the number
of diagnosed comorbidities recorded for each individual.
Body mass index (BMI) was calculated using the height
and weight data and categorised according to the WHO
classification [16].
After excluding participants without a recorded viral
load, the data were summarised descriptively, overall,
and by gender. Characteristics were compared by gender
using χ2tests for categorical variables and Wilcoxon rank
sum tests for continuous variables. Logistic regression
models were used to examine the association between a
detectable viral load and comorbidity, the number of co-
morbidities, and the four comorbidity indicators de-
scribed above. In the multivariable model exploring the
association between a detectable viral load and comor-
bidity, indicator iv) was used as the measure of overall
comorbidity as it incorporated those who were measured
as hypertensive on the day of recruitment into the study,
comorbidity recorded in clinic folders and self-reported
comorbidity.
Potential confounders included in the multivariable
analysis were: smoking, BMI, CD4 count, age, and sex.
Initially, smoking history was included in models using
two indicators to represent never smoked, ex-smoker,
and current smoker. BMI was considered using four in-
dicators to represent underweight (BMI < 18·5), normal
(BMI; 18·5–24·9), overweight (BMI 25–29·9) and obese
(BMI ≥30).
However, in univariable analysis, odds ratio (OR) esti-
mates were similar for the “ever smoked” and “current
smoker” categories, and the normal and underweight
BMI categories, and so these categories were grouped
for parsimony in all subsequent analyses. We considered
all variables that were significant at univariable level (p
value < 0·10) for the multivariable model. For the final
multivariable model, we explored interactions between
sex and smoking, and sex and BMI given the known
gender differences in smoking and BMI patterns in this
population. All analyses were conducted using STATA
SE 13 statistical package. Sensitivity analyses were also
performed using data only for participants with a viral
load measurement within 12 months of the interview
date and re-running the final multivariable model.
Results
Figure 1 reports participant recruitment and retention
for analysis. Among those who were eligible for analysis
(N = 318, Table 1), 75% were female and the median age
was 39 years among females and 42 years among males,
p < 0·001. The median BMI for females and males was
29 and 22 (p = < 0·001) respectively, with 10% of males
classified as obese compared to 45% of females. Signifi-
cantly more men had ever smoked and were current
smokers compared to women, 64% versus 9% ever
smoked respectively (p = < 0·001), and 50% versus 4%
were current smokers.
The median duration on ART was 4 years (IQR 2–7
years) and a significantly greater proportion of men had
a low CD4 count (< 350) compared to women (46% vs
25% respectively; p = < 0·001) (Table 2). The median time
since last CD4 measure was 8 months (IQR 4–12
months). Nineteen percent of the study population had
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a detectable HIV viral load (> 40 copies/ml), and 8% had
viral load > 1000 copies/ml. The median time since last
viral load was 7 months (IQR 4–11months).
Overall the majority of participants had only one co-
morbidity (Fig. 2). Figure 3 illustrates the reported preva-
lence of comorbidities according to the source of
diagnoses. Using indicator iii) (comorbidity on self-report
or folder-review), the prevalence of comorbidity was 20%
(95% CI 0.15–0.25), which was higher compared to using
indicator i) (14% (95% CI 0.10–0.18)) or ii) (19% (95% CI
0.14–0.23)). While there was overlap between the two
sources, additional reports came from each source indi-
vidually. Overall, 69% of indicator ii) diagnoses had also
been detected by indicator i), with 70, 92, 13, 57% of
Fig. 1 Flowchart of Participant Recruitment and Retention for Analysis
Table 1 Demographics of the sample, overall and by sex
Demographic characteristics Sample Population n = 318 (%) Male n = 80 (%) Female n = 238(%) Chi2 P Value
Age: Median (IQR) 39 (34–45) 42 (37–47) 39 (33–44) < 0.001c
25–34 82 (26) 14 (18) 68 (28) 0.07
35–44 145 (46) 35 (43) 110 (46)
45–54 65 (20) 23 (29) 42 (18)
54 > 26 (8) 8 (10) 18 (8)
BMI: (n = 316; inc. 79 males) 28 (23–32) 22 (19–26) 29 (25–34) < 0.001c
Median (IQR)
Underweight 20 (6) 12 (15) 8 (3) < 0.001
Normal 96 (30) 43 (55) 53 (22)
Overweight 85 (28) 16 (20) 69 (30)
Obese 115 (36) 8 (10) 107 (45)
Smoker
Yes currently 50 (16) 40 (50) 10 (4) < 0.001
Ex-smoker 23 (7) 11 (14) 12 (5)
Never 245 (77) 29 (36) 216 (91)
Pack years amongst ever smokers: median (IQR) 3 (1–6) 4 (1–7) 1 (0–2) < 0.001c
Significant results in italics c Wilcoxon rank sum test. N = 318 unless otherwise indicated
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hypertension, diabetes, CRD, and epilepsy indicator ii) diag-
noses also detected in indicator i) respectively. Of the 307
participants who had blood pressure measured on the day
of interview (11 participants did not have blood pressure
measured due to unavailability of an appropriate cuff size),
36% (n = 109) were found to be hypertensive. Of these, less
than a third (28% (n = 31; 95% CI 0.21–0.38) had a previous
diagnosis of hypertension. Including this diagnosis of
hypertension on the day of interview in the definition of co-
morbidity (indicator iv)) increased the overall prevalence of
comorbidities to 43% (95% CI 0.38–0.48).
In univariable regression models, none of the four co-
morbidity indicators, or the ordinal variable measuring
number of comorbidities were significantly associated
with a detectable HIV viral load (Table 3). In contrast,
ever smoking, being normal/underweight (BMI ≤ 24·9),
Table 2 Treatment-related characteristics, overall and by sex
Treatment-related Characteristics Sample
n = 318 (%)
Male
n = 80 (%)
Female
n = 238 (%)
Chi2 P Value
Duration of ART (years): Median (IQR) 4 (2–7) 3 (2–6) 4 (2–7) 0.09c
0.5–2.5 89 (27) 26 (33) 63 (26)
2.6–4.0 76 (24) 25 (31) 51 (22) 0.09
4.1–6.0 59 (19) 12 (15) 47 (20)
> 6.0 94 (30) 17 (21) 77 (32)
Most recent Viral load (copies/ml)
Detectable 60 (19) 18 (22) 42 (18) 0.34
Not detectable (LDL/< 40) 258 (81) 62 (78) 196 (82)
Time since last VL: Median (IQR) (months) 7 (4–11) 5 (3–10) 7 (4–11) 0.21c
Most recent CD4 count (n = 299; inc. 76 males)
Binary Indicator (cells/mm3):
Low (≤350) 92 (31) 35 (46) 57 (25) < 0.001
High (> 350) 207 (69) 41 (54) 166 (75)
Categorised CD4
Low: 0–299 73 (24) 28 (37) 45 (20) < 0.001
300–449 58 (20) 17 (22) 41 (19)
450–599 79 (26) 21 (28) 58 (26)
High: ≥600 89 (30) 10 (13) 79 (35)
Time since last CD4 measurement: Median (IQR) (months) (n = 299; inc. 76 males) 8 (4–12) 6 (3–11) 8 (4–12) 0.31c
Significant results in italics. c Wilcoxon rank sum test. N = 318 unless otherwise indicated
Fig. 2 Number of participants with indicator iii) stratified by the number of comorbidities. CRD (Chronic Respiratory Disease)
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and having a low CD4 count (CD4 < 300 cells/mm3)
were associated with higher odds of having a detectable
viral load. The final multivariable model included age,
sex, having ever smoked, BMI, CD4 count, and comor-
bidity indicator (iv) (Table 3). Significantly higher odds
of a detectable HIV viral load were associated with being
female (OR 3·26; p = 0·02), and having ever smoked
compared to never smoked (OR 3.95; p = 0· < 001). Indi-
viduals aged ≥35 years had significantly lower odds of
having a detectable HIV viral load compared to those
aged < 35 years (OR 0·40; p = 0·02). Higher CD4 counts
were also associated with significantly lower odds of a
detectable viral load: compared to a referent of CD4 <
300 cells/mm3, CD4 300–449 cells/mm3 (OR 0·28; p = <
0·001), CD4 450–599 cells/mm3 (OR 0·12; p = < 0·001)
and, CD4 ≥ 600 cells/mm3 (OR 0·12; p = < 0·001). BMI
remained significant at the 10% level (p < 0·1) in the final
model but effect estimates remained similar to the size
of those in the univariate model suggesting normal /
underweight was associated with higher odds of a de-
tectable HIV viral load compared to being obese. The in-
teractions between sex and smoking, and sex and BMI
were in turn added to the final model, however neither
interaction made a statistically significant contribution
to the model and they were not retained. Sensitivity ana-
lyses were conducted excluding 52 individuals whose
most recent viral load measurement was not within 12
months of interview. Excluding these individuals did not
significantly change the model results (data not shown).
Discussion
This study investigated the association between a detect-
able HIV viral load and the presence of comorbidities.
We found no statistically significant association be-
tween a detectable HIV viral load and the presence of
any comorbidity (comorbidity indicator iv). This is con-
sistent with a study conducted between 2004 and 2009
which found no association between a detectable HIV
viral load and hypertension in HIV-infected adults on
ART in SA [11]. In contrast, 2 studies based in the US
over a similar time period examined HIV-infected adults
on ART and found an association between comorbidity
and a detectable HIV viral load [4, 6]. Neither study de-
scribed the period of time participants were on ART and
in one study all participants were treated for diabetes,
hypertension, or both [4, 6]. Notably these studies had
different definitions for viraemia. Two recent papers
noted an association between low level viremia (> 50–
1000 copies/ml) and increased risk of virological failure
[17, 18]. While 8 % of our sample had a viral load of
greater than 1000 copies/ml, due to insufficient statis-
tical power, we did not sub-categorise viral load, and this
may have contributed to our differing results. A second
possible explanation is selection bias. Given that
non-attendance is associated with a detectable HIV viral
load, and all participants in our study were attending
their clinic appointment, this could be a source of bias
[19] as those within the study may be more likely than
the general population to be virologically suppressed.
The high proportion of participants with measured
hypertension on the interview day without a previous
diagnosis of hypertension also indicates under diagnosis
of comorbidity, and suggests that data reporting hyper-
tension diagnoses are likely to be an underestimate of
true prevalence [20, 21]. A meta-analysis looking at the
prevalence of hypertension in SSA found that of those
with hypertension, only 7–56% were aware of the
Fig. 3 Prevalence of each comorbidity by indicators i) to iii). CRD (Chronic Respiratory Disease)
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diagnosis prior to the study [22]. White coat hyperten-
sion may contribute to the higher prevalence of mea-
sured hypertension, although research suggests that the
presence of white coat hypertension may be associated
with sustained hypertension in the future [23]. The
prevalence of hypertension was consistent with that
found in HIV-infected adults who had been on ART for
over 1 year in SA [24]. However the prevalences of dia-
betes, CRD, and epilepsy found in this study were lower
in comparison to another study surveying the SA adult
population presenting to primary health care in 2010
[21]. This may be due to the fact that the majority of
participants in that study were HIV uninfected. A study
on HIV-infected persons over 50 years old in rural South
Africa reported better functional ability, quality of life
and overall health state (measured using three instru-
ments: disability index, quality of life and composite
health score) than HIV-affected participants. This sug-
gests that enhanced healthcare received as part of HIV
care could benefit overall wellbeing of HIV-infected
older people [25]. However, there are little data on
NCDs in HIV-infected persons [21].
Our results indicate that age < 35 years, female gender,
ever smoking, and low CD4 count were associated with
a detectable HIV viral load. Whilst this study had 75%
female participants, this gender ratio is typical for ART
clinics in this [26] and other settings [2, 27]. In addition,
in Khayelitsha, this gender ratio persists in the NCD
clinics due to the overall predominance of females at-
tending primary care services [2]. The significant gender
differences seen in BMI, smoking, and CD4 (Tables 1
and 2) may play a role. However, this study was not
powered to stratify analyses by gender.
Comparing the comorbidity measurement between the
HIV clinic folders and self-report, a lower level of co-
morbidity was found in the HIV clinic folders than was
self-reported on interview. Inaccuracy in self-report may
be a factor. For example, self-reported diagnoses of CRD
were very few; possibly due to low levels of awareness of
the diagnosis, or about CRD symptoms. It may also be a
reflection of the absence of screening for NCDs in the
HIV-infected population. The lack of integration be-
tween HIV and NCD healthcare systems at the time of
this study is also a significant barrier to this ascertain-
ment of NCD co-morbidity in this population group.
Past studies have recognised this likely under-diagnosis
of NCD alongside the paucity of data on NCD in
HIV-infected individuals in LMICs [14, 20, 21]. This is par-
ticularly relevant as research suggests that HIV-infected in-
dividuals have a greater burden of NCDs than non-infected
adults of the same age [2, 5, 28]. ART may also contribute,
as studies have found that HIV-infected groups on ART
have a higher prevalence of hypertension compared to simi-
lar groups not on ART [2, 29]. Amongst HIV-infected
individuals with comorbidity in Soweto, SA, research sug-
gests that rather than seeing their conditions as separate
biomedical entities, patients transmute their conditions into
an overall perception of chronic suffering [7]. This contrasts
with the separation of healthcare services into distinct bio-
medical categories. The implications of the fragmented ver-
tical systems are seen at Ubuntu clinic: separate folders for
HIV and other primary healthcare service means
treatment-related decisions, diagnoses, and measures of
HIV control from one clinic may not be communicated to
and recorded by all. Strengthening of health systems
through integration of care is therefore needed, for example
through sharing of clinic folders and data information sys-
tems, as well as implementation of routine active screening
for common NCDs in HIV-infected persons. These strat-
egies would serve to provide improved holistic chronic care
for these patients, as well as enabling future research on
the interaction between these co-occurring diseases [2, 3,
7].
Examining risk factors for comorbidity, our results
highlight the importance of smoking and BMI as signifi-
cant risk factors for comorbidity. Higher levels of smok-
ing in HIV-infected compared to non-infected
populations have been reported and previous studies
have found that both HIV infection and smoking inde-
pendently impact T-cell function and together signifi-
cantly worsen the immune profile [30, 31]. Persistent
immune activation is associated with increased morbid-
ity and mortality [31]. Our finding that smoking was sig-
nificantly associated with a detectable HIV viral load was
also reported in a study of HIV-infected persons in the
low HIV-burden setting of the United States of America
[32] and merits further investigation given evidence that
suggests tobacco smoking increases the immune activa-
tion in HIV-infected adults and is a known risk factor
for NCD [31].
Non-nucleoside reverse transcriptase inhibitors antire-
trovirals are used in SA and their side effects of lipody-
strophy and truncal obesity may increase the risk of
hypertension and diabetes [2]. This is particularly im-
portant in women due to the gender discrepancy in the
prevalence of obesity found in this study, and others in
SA [2, 33]. Previous research has recommended the in-
clusion of data on NCD risk factors such as smoking sta-
tus and BMI in clinical HIV databases to encourage
routine monitoring and to inform clinical decision mak-
ing such as choice of ART drug prescription [31, 34]. It
should however be noted that even in a vertical system,
the CD4 count and viral load, important markers of dis-
ease control, were not always recorded in HIV clinic
folders of the participants in this study. Given that these
markers are an important aspect of HIV care, interven-
tions to integrate inclusion of data on comorbidity risk
factors and coexisting NCD should aim to also improve
George et al. BMC Infectious Diseases          (2019) 19:348 Page 9 of 11
disease monitoring for HIV to avoid treatment failure
and drug resistance [35].
As life expectancy and quality of life among persons
with HIV improves due to the ART roll out, NCD
co-morbidity is expected to increase, necessitating better
integration between these vertical health systems [2, 3].
HIV/NCD co-morbidity is associated with increasing
complexity in the management of comorbid diseases due
to disease-drug and drug-drug interactions [28]. These
interactions make access by clinicians to comprehensive
information about patients necessary to inform care and
decision-making.
Strengths and limitations
This study addresses the need to investigate HIV/NCD
comorbidity and the association with poor HIV viral
suppression. However, there were some limitations. Des-
pite the fact that 80% of HIV-infected individuals live in
SSA and evidence describes a growing NCD prevalence
in these HIV-infected populations, [2, 36] there is sparse
evidence in LMICs about the effect of HIV/NCD comor-
bidity on HIV control [4, 6]. Furthermore there are little
data on the models of care needed and possible interac-
tions between these colliding epidemics and research in
LMICs [36].
Our final sample had a slightly lower prevalence of co-
morbidity than hypothesised (43% vs 50%) and was smaller
than the target number (298 vs 330), which may have re-
duced our ability to observe a statistically significant associ-
ation between presence of comorbidity and detectable viral
load. Some reduction in our final sample for analysis was
because we were unable to measure blood pressure in all
participants due to a lack of a sufficiently large cuff size for
the most obese participants. Given the known link between
hypertension and obesity, a greater proportion of this group
may have been hypertensive. Thus, our estimate of hyper-
tension prevalence may underrepresent the true level in this
population. Furthermore, SA guidelines require multiple
readings to make a diagnosis of hypertension. Although this
was not feasible in this study, we did record previous diag-
noses, in addition to measured elevated blood pressure. We
did not measure adherence to medication. This may have
been a confounder as past studies have suggested that those
with poor adherence to ART, for a variety of reasons in-
cluding substance abuse, a common risk factor in South
Africa, may have poor adherence to medication for comor-
bidity resulting in a detectable viral load alongside higher
blood pressure [6]. The gender ratio and sample size of this
study limited the statistical power of this study to stratify
the analyses by gender. Research suggesting that HIV-in-
fected men have poorer health-seeking behaviour compared
to women and hence a higher AIDS mortality rate highlight
the importance of further research exploring the effect of
gender on the association between viral load and
multimorbidity; and the need for gender-specific strategies
to encourage earlier enrolment into HIV care [27]. Given
the vertical nature of the health system and absence of rou-
tine screening for NCDs in this HIV clinic, under-diagnosis
of NCDs may have limited our ability to detect a significant
association between NCD co-morbidity and viral load. Fi-
nally, the unknown timing of comorbidity diagnoses and
the cross-sectional nature of our study meant we were un-
able to investigate causality in exploring comorbidity risk
factor associations.
Conclusion
We found no association between a detectable HIV viral
load and comorbidity. Lower NCD prevalence in clinic
records than self-report and a higher level of hyperten-
sion on the day than self-reported or recorded in clinic
folders suggest under-diagnosis of NCDs in this popula-
tion. This potential under-detection of NCDs may differ
from a high-income setting and have contributed to our
finding of a null association. This suggests the need for
further research and better detection of, and screening
for NCDs. An integrated chronic care system would
allow enhanced detection, and dual management of HIV
and NCDs and their risk factors, in addition to promot-
ing an integrated approach to chronic infectious and
NCD prevention.
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